OLMA Olema Pharmaceuticals

Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference

Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- (“Olema”, “Olema Oncology”, Nasdaq: OLMA) today announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023, at 2:15 p.m. PT (5:15 p.m. ET).

A live webcast of the presentation and any accompanying presentation materials will be available under the News & Events section of Olema’s Investor Relations website at . The webcast will be archived for at least 30 days.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK 4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. 

IR Contact:

Courtney Dugan, Vice President, Investor Relations and Communications

Media Contact:

Ignacio Guerrero-Ros, Ph.D., Russo Partners

646-942-5604



EN
03/01/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Olema Pharmaceuticals

 PRESS RELEASE

Olema Oncology to Participate in Upcoming Investor Conferences

Olema Oncology to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) --  (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences: Citi’s 2025 Biopharma Back to School ConferenceDate and Time: September 2, 2025 at 4 p.m. ETFormat: Fireside ChatLocation: Boston, MA Wells Fargo 2025 Healthcare ConferenceDate and...

 PRESS RELEASE

Olema Oncology Reports Second Quarter 2025 Financial and Operating Res...

Olema Oncology Reports Second Quarter 2025 Financial and Operating Results Selected 90 mg once-daily palazestrant for Part 2 of the OPERA-01 Phase 3 monotherapy trial and for the OPERA-02 Phase 3 trial in combination with ribociclibOPERA-01 enrollment ongoing with top-line data expected in the second half of 2026; OPERA-02 on track to initiate in Q3 2025Mature data from the Phase 1b/2 study of palazestrant in combination with ribociclib to be presented at ESMO 2025 Ended the second quarter with $361.9 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Aug. 11, 202...

 PRESS RELEASE

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 563...

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 130,000 shares of the Company's common stock, effective as of August 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Direct...

 PRESS RELEASE

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 563...

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 154,500 shares of the Company's common stock, effective as of July 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Director...

 PRESS RELEASE

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 563...

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN FRANCISCO, June 03, 2025 (GLOBE NEWSWIRE) -- (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to 11 new employees to purchase an aggregate of 322,000 shares of the Company's common stock, effective as of June 2, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch